All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

When should a Hyper CVAD regimen be considered for ALL? And when not?

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the ALL Hub spoke to Elias Jabbour, MD Anderson Cancer Center, Houston, US. We asked, When should a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone, alternated with methotrexate and cytarabine (hyper-CVAD) regimen be considered for ALL? And when not?

When should a Hyper CVAD regimen be considered for ALL? And when not?

Jabbour begins by outlining how this pediatric inspired regimen became a standard of care. He goes on to explain how by monitoring toxicities, disease and patient profiles, adjustments can be made, e.g. dose variations or drug omissions. He highlights that future treatment is moving away from intensive chemotherapy in favor of further integration of immunotherapy into the regimen.

 

Share: